CRISM Therapeutics Corporation (AIM:CRTX)
London flag London · Delayed Price · Currency is GBP · Price in GBX
10.75
0.00 (0.00%)
Aug 14, 2026, 4:58 PM GMT

CRISM Therapeutics Cash Flow Statement

Millions GBP. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-1.9-0.61-0.2-2.5-0.89
Depreciation & Amortization
0.020.020.02-0.2
Other Operating Activities
--0.290.07-0.4-0.67
Change in Accounts Receivable
-0.12-0.37---
Change in Accounts Payable
0.040.310.02--
Operating Cash Flow
-1.97-0.93-0.1-2.92-1.35
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-----0.31
Cash Acquisitions
-2.36---
Divestitures
----4.53
Sale (Purchase) of Intangibles
-0.03-0.03-0.01--
Other Investing Activities
----0.420.24
Investing Cash Flow
-0.032.33-0.01-0.424.46

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
1.930.1-0.29-
Common Dividends Paid
--0.05---
Other Financing Activities
-0.09-0.12-0.52-
Financing Cash Flow
1.84-0.07-0.8-

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0-0.05---0.23
Net Cash Flow
-0.151.28-0.11-2.542.87

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1.97-0.93-0.1-2.92-1.67
Free Cash Flow Growth
-----
Free Cash Flow Margin
-851.51%-3732.00%-217.78%--
Free Cash Flow Per Share
-0.05-0.03-6.13-0.34-0.19
Levered Free Cash Flow
-1.27-0.6519-1.91-18.57
Unlevered Free Cash Flow
-1.27-0.6519.02-1.91-18.57

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
---0.04--
Change in Working Capital
-0.08-0.060.02--